This site is intended for health professionals only
Saturday 22 September 2018
Share |

Topic: glycaemic control

May 29, 2015
Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type II diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance.

Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type II diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance.

Synjardy® combines two products with different mechanisms of action to improve glycaemic control in patients with T2D. Side effects identified with Synjardy® are consistent with known safety profiles of the individual compounds.
 

February 19, 2015
CeQur® SA, a leader in simple insulin infusion for people with type 2 diabetes, announced preliminary results from a new study demonstrating that the company’s PaQ® Insulin Delivery Device improves glycaemic control among people with type 2 diabetes. The data were presented at the 8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris.

CeQur® SA, a leader in simple insulin infusion for people with type 2 diabetes, announced preliminary results from a new study demonstrating that the company’s PaQ® Insulin Delivery Device improves glycaemic control among people with type 2 diabetes. The data were presented at the 8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris.